Biologics/Immunotherapy News

Biologics designed to counter type 2 inflammation reduced asthma exacerbations in real world settings, with dupilumab having the most impact, according to a study in he Journal of Allergy and Clinical Immunology: In Practice.

Patients with asthma exacerbations and elevated blood eosinophils and fractional exhaled nitric oxide saw fewer exacerbations with lebrikizumab, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice.

Children at high risk for reactions in oral immunotherapy for food allergy may benefit from sublingual immunotherapy before oral food challenges, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice.

Sublingual immunotherapy tablets improved quality of life for patients with allergic rhinitis with and without conjunctivitis, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice.

WASHINGTON — Physicians have a variety of safe and effective biologic choices for treating children with asthma, according to a presentation at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Treatment-emergent adverse events with epicutaneous immunotherapy for peanut allergy grew less frequent and severe over 5 years, according to a poster at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Patients with chronic spontaneous urticaria experienced better quality of life with dupilumab compared with placebo, according to two posters presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Children taking dupilumab for atopic diseases received measles, mumps and rubella and varicella immunizations later than other children, according to a poster presented here.

WASHINGTON — Urticaria treatment guidelines in the United States include more options than the World Allergy Organization’s guidelines, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Children with severe allergic asthma and serum total IgE levels between 1,500 kU/L and 3,300 kU/L as well as food allergy benefitted from omalizumab, according to a study published in Pediatric Allergy and Immunology.